2024 [Google Scholar] 254.Hasan B., Thompson W.G., Almasri J., Wang Z., Lakis S., Prokop L.J., Hensrud D.D., Frie K.S., Wirtz M.J., Murad A.L., et al
The Future of GLP-1 Medications GLP-1 therapy is no longer just about diabetesits a cornerstone of obesity medicine
Lower prices but keep them high enough to provide long-term innovation incentives : While reducing prices is critical, they should remain sufficient to incentivize research and development at pharmaceutical companies
Nakamura T, Harada K, Kamiya T, Takizawa M, Kppers J, Nakajima K, et al
Shotsy automatically calculates when your next dose is due and reminds you accordingly
Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: filling the gaps